Head-to-head evidence
Evorpacept vs Maplirpacept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD47 · full Multiple Myeloma pipeline
Evorpacept
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Maplirpacept
Developed by Pfizer
NCT03530683 · Phase 1 · terminated
This is an open, non-randomized, single-arm dose-escalation study without a comparator or blinding, designed to characterize side effects and find a dose rather than test whether the drug works. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
This is an interim readout of the monotherapy dose-escalation portion of the study, not the final result for the full trial.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evorpacept's landscape · Maplirpacept's landscape